Mode
Text Size
Log in / Sign up
Phase 3 Completed N=119 Randomized Double-blind Treatment

Safety and Efficacy of IQP- AK-102 in Reducing Body Weight

Source: ClinicalTrials.gov NCT01905956 ↗
Enrolled (actual)
119
Serious AEs
0.9%
Results posted
Mar 2016
Primary outcomePrimary: Mean Change in Body Weight From Baseline to Week 12 — 3.53; 0.14 kilogram (kg)

Summary

The individual ingredients in IQP-AK-102 have been widely used. Backed by data from several studies demonstrating their efficacy, we are conducting this study to look into the efficacy and safety of this novel combination of three fibres, in appetite regulation.

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Change in Body Weight From Baseline to Week 12
3.53; 0.14
SECONDARY
Mean Change in Waist and Hip Circumference (cm) From Baseline to Week 12
2.12; 0.92; 2.25; 1.07
SECONDARY
Mean Change in Body Fat Content (%) From Baseline to Week 12
0.95; 0.08
SECONDARY
Mean Change in Body Fat Mass (kg) From Baseline to Week 12
1.32; 0.05
SECONDARY
Food Craving Questionnaire (FCQ)
2.65; 2.74; 2.17; 2.47; 1.98; 2.34
SECONDARY
Global Evaluation of Efficacy by the Investigators
31; 1; 18; 6; 4; 19
SECONDARY
Global Evaluation of Efficacy by the Subjects
28; 1; 22; 6; 4; 22
SECONDARY
Global Evaluation of Safety by the Investigators
46; 35; 6; 7; 0; 1
SECONDARY
Global Evaluation of Safety by the Subjects
46; 37; 7; 7; 0; 1

Eligibility Criteria

Inclusion Criteria

  • Age 18 to 65 years
  • 25≤BMI≤35
  • Expressed desire for weight loss
  • Accustomed to 3 main meals/day
  • Generally in good health
  • Consistent and stable body weight 3 months prior to study enrolment
  • Consistent regular physical activity
  • Commitment to avoid the use of other weight loss products during study
  • Commitment to adhere to diet and lifestyle recommended for the study

Exclusion Criteria

  • Known sensitivity to the ingredients of the device
  • Presence of any active gastrointestinal disease
  • Malabsorption disorders
  • Pancreatitis
  • Stenosis in the GI tract
  • Bariatric surgery
  • Any other reason deemed suitable for exclusion, per investigator's judgement
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01905956). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search